The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence

Magdalena Urbańska, Hania Szajewska, Magdalena Urbańska, Hania Szajewska

Abstract

We aimed to systematically evaluate evidence on the effectiveness of Lactobacillus reuteri DSM 17938 (L. reuteri) for treating and preventing diseases in infants and children. MEDLINE and the Cochrane Library were searched in December 2013, with no language restrictions, for relevant randomized controlled trials (RCTs) and meta-analyses. The search was updated in April 2014. One systematic review and 14 RCTs met the inclusion criteria. The use of L. reuteri may be considered in the management of acute gastroenteritis as an adjunct to rehydration. There is some evidence that L. reuteri is effective in reducing the incidence of diarrhea in children attending day care centers. There is no evidence of effectiveness of L. reuteri in preventing nosocomial diarrhea in children. The administration of L. reuteri is likely to reduce crying time in infants with infantile colic in exclusively or predominantly exclusively breast-fed infants, but not in formula-fed infants. More studies are needed. Preliminary data suggest that L. reuteri may be effective in the prevention of some functional gastrointestinal disorders, such as colic and regurgitation. This innovative approach needs further evaluation by an independent research team. Preliminary evidence provides a rationale for further assessing the efficacy of L. reuteri for treating functional constipation or functional abdominal pain. However, it is too soon to recommend the routine use of L. reuteri for these conditions. There are no safety concerns with regard to the use of L. reuteri in nonimmunocompromised subjects. There are also data to support the safety of using L. reuteri in preterm infants.

Conclusion: Our results precisely define current evidence on the effects of the administration of L. reuteri DSM 17938 to the pediatric population.

Figures

Fig. 1
Fig. 1
Infantile colic. L. reuteri DSM 17938 compared with placebo—effect on crying time on day 21
Fig. 2
Fig. 2
The effect of L. reuteri DSM 17938 compared with placebo on necrotizing enterocolitis (NEC), death, sepsis, and feeding intolerance episode frequency in preterm infants

References

    1. Agustina R, Bovee-Oudenhoven IM, Lukito W, Fahmida U, van de Rest O, Zimmermann MB, Firmansyah A, Wulanti R, Albers R, van den Heuvel EG, Kok FJ. Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1–6 years. J Nutr. 2013;143(7):1184–1193. doi: 10.3945/jn.112.166397.
    1. Axelson LT, Chung TC, Dobrogosz WJ, Lindgren SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis. 1989;2:131–136. doi: 10.3109/08910608909140210.
    1. Chung TC, Axelsson L, Lindgren SE, Dobrogosz WJ. In vitro studies on reuterin synthesis by Lactobacillus reuteri. Microb Ecol Health Dis. 1989;2:137–144. doi: 10.3109/08910608909140211.
    1. Coccorullo P, Strisciuglio C, Martinelli M, Miele E, Greco L, Staiano A. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo- controlled study. J Pediatr. 2010;157(4):598–602. doi: 10.1016/j.jpeds.2010.04.066.
    1. Dinleyici EC, PROBAGE Study Group. Vandenplas Y. Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children. Acta Paediatr. 2014
    1. Egervärn M, Lindmark H, Olsson J, Roos S. Transferability of a tetracycline resistance gene from probiotic Lactobacillus reuteri to bacteria in the gastrointestinal tract of humans. Antonie Van Leeuwenhoek. 2010;97(2):189–200. doi: 10.1007/s10482-009-9401-0.
    1. FDA (2012) Available via DIALOG: . Accessed 2 Mar 2014
    1. Food and Agriculture Organization of the United Nations (FAO) (2001) Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Available via DIALOG: . Accessed 25 Feb 2014
    1. Francavilla R, Lionetti E, Castellaneta S, Ciruzzi F, Indrio F, Masciale A, Fontana C, La Rosa MM, Cavallo L, Francavilla A. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea–a double-blind study. Aliment Pharmacol Ther. 2012;36(4):363–369. doi: 10.1111/j.1365-2036.2012.05180.x.
    1. Garofoli F, Civardi E, Indrio F, Mazzucchelli I, Angelini M, Tinelli C, Stronati M. The early administration of Lactobacillus reuteri DSM 17938 controls regurgitation episodes in full-term breastfed infants. Int J Food Sci Nutr. 2014
    1. Grześkowiak Ł, Isolauri E, Salminen S, Gueimonde M. Manufacturing process influences properties of probiotic bacteria. Br J Nutr. 2011;105(6):887–894. doi: 10.1017/S0007114510004496.
    1. Gutierrez- Castrellon P, Lopez- Velazquez G, Diaz- Garcia L, Jimenez- Gutierrez C, Mancilla- Ramirez J, Estevez- Jimenez J, Parra M. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics. 2014;133:e904. doi: 10.1542/peds.2013-0652.
    1. Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, Ballardini E, Bisceglia M, Cinquetti M, Brazzoduro E, Del Vecchio A, Tafuri S, Francavilla R. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr. 2013;168(3):228–233. doi: 10.1001/jamapediatrics.2013.4367.
    1. Indrio F, Riezzo G, Raimondi F, Bisceglia M, Filannino A, Cavallo L, Francavilla R. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Investig. 2011;41(4):417–422. doi: 10.1111/j.1365-2362.2010.02425.x.
    1. Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol. 2009;11(9):35. doi: 10.1186/1471-2180-9-35.
    1. Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis. 2008;14(8):1068–1083. doi: 10.1002/ibd.20448.
    1. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299(5):G1087–G1096. doi: 10.1152/ajpgi.00124.2010.
    1. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol. 2012;302(6):G608–G617. doi: 10.1152/ajpgi.00266.2011.
    1. Oncel MY, Sari FN, Arayici S, Guzoglu N, Erdeve O, Uras N, Oguz SS, Dilmen U. Lactobacillus reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2014;99(2):F110–F115. doi: 10.1136/archdischild-2013-304745.
    1. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol. 2001;2:43–53.
    1. Rojas MA, Lozano JM, Rojas MX, Rodriguez VA, Rondon MA, Bastidas JA, Perez LA, Rojas C, Ovalle O, Garcia-Harker JE, Tamayo ME, Ruiz GC, Ballesteros A, Archila MM, Arevalo M. Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. Pediatrics. 2012;130(5):e1113–e1120. doi: 10.1542/peds.2011-3584.
    1. Romano C, Ferrau V, Cavataio F, Iacono G, Spina M, Lionetti E, Comisi F, Famiani A, Comito D (2010) Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 824
    1. Rosander A, Connolly E, Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol. 2008;74(19):6032–6040. doi: 10.1128/AEM.00991-08.
    1. Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S, Matteuzzi D. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126(3):e526–e533. doi: 10.1542/peds.2010-0433.
    1. Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, Heine RG, Stock A, Barr RG, Wake M. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ. 2014;1(348):g2107. doi: 10.1136/bmj.g2107.
    1. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;162:257–262. doi: 10.1016/j.jpeds.2012.08.004.
    1. Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, Shamir R, Vandenplas Y, Weizman Z (2014) Use of Probiotics for Management of Acute Gastroenteritis: A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 58(4):531–539
    1. Szajewska H, Urbańska M, Chmielewska A, Weizman Z, Shamir R. Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children. Benefic Microbes. 2014;24:1–9.
    1. Talarico TL, Casas IA, Chung TC, Dobrogosz WJ. Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri. Antimicrob Agents Chemother. 1988;32(12):1854–1858. doi: 10.1128/AAC.32.12.1854.
    1. Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol. 2004;70(2):1176–1181. doi: 10.1128/AEM.70.2.1176-1181.2004.
    1. Wanke M, Szajewska H. Lack of an effect of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in children: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2012;161(1):40–43.e1. doi: 10.1016/j.jpeds.2011.12.049.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir